GFT505 80mg

DRUG5 trials

Sponsors

Genfit

Conditions

Abdominal ObesityAtherogenic DyslipidaemiaImpaired Glucose ToleranceInsulin ResistanceNon-Alcoholic Steatohepatitis (NASH)Type II Diabetes Mellitus

Phase 2

Study With GFT505 (80mg) Versus Placebo in Patients With Type 2 Diabetes Mellitus

CompletedNCT01261494

GenfitType II Diabetes Mellitus

Start: 2010-12-31End: 2011-06-30Updated: 2011-07-13

Pilot Study With GFT505 (80mg) in Patients With Insulin Resistance and Abdominal Obesity

CompletedNCT01271777

GenfitAbdominal Obesity, Insulin Resistance

Start: 2011-01-31End: 2011-11-30Updated: 2012-09-24

Pilot Study With GFT505 (80mg) in Atherogenic Dyslipidaemic Patients With Abdominal Obesity

CompletedNCT01271751

GenfitAbdominal Obesity, Atherogenic Dyslipidaemia

Start: 2009-01-31End: 2009-11-30Updated: 2011-01-07

Pilot Study With GFT505 (80mg) in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity.

CompletedNCT01275469

GenfitAbdominal Obesity, Impaired Glucose Tolerance

Start: 2009-06-30End: 2010-01-31Updated: 2011-01-12

Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)

CompletedNCT01694849

GenfitNon-Alcoholic Steatohepatitis (NASH)

Start: 2012-09-30End: 2015-12-31Updated: 2022-11-03

Related Papers

An update on the pharmacological treatment of nonalcoholic fatty liver disease: Beyond lifestyle modifications

Clinical Liver Disease2018-04-0139 citations

Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis

PLoS ONE2016-06-27306 citations

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.

2016-02-11778 citations